Aspirin and healthy longevity within racial and ethnic minoritized older adults in the United States

For decades, the medical community has debated whether a simple, inexpensive daily pill could help older adults live longer, healthier lives. The idea centers on low-dose aspirin, a medication long known to thin the blood and prevent clots. For many years, doctors believed this mechanism might protect the aging heart and brain, potentially delaying the onset of disability, dementia, or death. However, a major global study known as ASPREE previously tested this idea in a broad group of older adults and found no overall benefit. In fact, the study suggested that for the average person over 70, the risks of bleeding outweighed any potential gains. Yet, as researchers looked closer at the data, they noticed something subtle: the results were not the same for everyone. Specifically, there were hints that the pill might work differently for people from racial and ethnic minority groups in the United States, who often face higher risks of chronic disease and disability. This new analysis asks a more precise question: rather than asking if the pill works for everyone, can we identify which specific individuals among these minority groups might actually benefit from it?

To answer this, a team of researchers turned to the data from the original ASPREE trial, focusing specifically on 1,270 participants in the United States who identified as either Black or Hispanic. These individuals were all over the age of 65 and had no history of heart disease, dementia, or persistent physical disability when they joined the study. They were randomly assigned to take either a low-dose aspirin every day or a placebo, a harmless pill that looked identical but contained no medicine. The researchers tracked them for five years, watching for the first occurrence of death, persistent physical disability, or dementia. Instead of simply comparing the two groups as a whole, the team used a sophisticated computer modeling technique to look at each person individually. This method allowed them to estimate how much a specific person's risk of these negative outcomes would change if they took aspirin versus if they took the placebo, based on their unique mix of age, health history, and lifestyle factors.

The results revealed a story far more complex than a simple "yes" or "no." When the researchers looked at the entire group of Black and Hispanic participants together, the data suggested a lower risk of disability or death for those taking aspirin compared to the placebo group, though this was an estimated association rather than a uniform effect. However, the most significant finding was that this benefit was not spread evenly across all participants. The computer models sorted the people into three distinct groups based on their predicted response to the medication. One group, characterized by a specific profile of higher health risks, showed a dramatic improvement. For these individuals—the "greatest predicted-benefit" subgroup—taking aspirin reduced their five-year risk of disability or death by approximately 11 percentage points compared to not taking it, though the statistical confidence interval for this estimate was wide and just barely excluded zero. In contrast, another group, who had a different health profile, showed no benefit at all, and for some, the data even hinted that the pill might be slightly harmful.

The people who stood to gain the most from the aspirin shared a recognizable set of traits. They tended to be slightly younger than the others in the study, more likely to live alone, and more likely to be current smokers. They also had higher rates of diabetes and obesity, higher blood pressure, and were more likely to be taking medication for high blood pressure. Paradoxically, they also had stronger handgrip strength and higher levels of hemoglobin in their blood. This specific combination of factors seemed to act as a signal that their bodies would respond well to the blood-thinning effects of the drug. Meanwhile, those who did not benefit often had different characteristics, such as lower blood pressure and no history of smoking. The researchers found that the traditional way of looking at data, which often treats everyone in a racial group as the same, would have missed these crucial differences. By looking at the individual details, they could see that the pill was a powerful tool for some, but not for others.

It is important to understand that these findings are a suggestion, not a final rule for doctors to follow immediately. Because this analysis was done after the original trial was completed, using a new type of computer model, the results need to be tested again in a fresh group of people before they can change medical practice. The researchers are careful to state that their work does not prove that aspirin is the right choice for every Black or Hispanic older adult. Instead, it suggests that the old approach of giving the same advice to everyone in a demographic group is too blunt. The study points toward a future where preventive care could be tailored to the individual, matching the right treatment to the person whose specific health profile indicates they will actually benefit. Until that future arrives, the message remains one of caution: while the data is promising for a specific subset of people, the decision to start taking aspirin for prevention should still be made carefully with a doctor, considering the risks and the lack of definitive proof for the general population.